Literature DB >> 33376110

Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia.

M Masudur Rahman1, Md Golam Kibria2, Hasina Begum3, Mazhar Haque4, Nigar Sultana5, Mahfuza Akhter6, A H M Rowshon7, Faruqe Ahmed2, Mahmud Hasan8.   

Abstract

INTRODUCTION: Since there is a paucity of data on the epidemiology of the non-alcoholic fatty liver disease (NAFLD), particularly in rural areas in Asia, we undertook such a study among the population of a rural community in Bangladesh with the aims to (1) determine the prevalence of non-obese and obese NAFLD, (2) compare the sociodemographic clinical and metabolic characteristics between non-obese and obese NAFLD subjects, and (3) determine the risk factors of NAFLD and no-nobese NAFLD.
METHODS: In this door-to-door survey, clinical examination, anthropometric measurements, biochemical tests and ultrasonography were performed on the adult population (≥18 years) of three villages in Bangladesh.
RESULTS: Of 1682, 1353 (80.44%) responded. After the exclusion of 48 subjects for alcohol consumption, HBsAg or anti-hepatitis C virus positivity, 1305 ((mean age 41.28±15.10 years, female 908 (69.6%)) were included in the final analysis. On ultrasonography, among the study population, 57 (4.4%) non-obese, 185 (14.2%) obese and, overall, 242 (18.5 %, (male 23.40%, female 16.4%, p=0. 003)) participants had NAFLD. NAFLD was detected in 57/804 (7.1%) of non-obese and 185/501 (36.93%) obese participants. Among the lean subjects, 24/592 (4.1%) had NAFLD. Among NAFLD subjects, 57 (23.55%) were non-obese, and 53 (22%) had raised alanine aminotransferase. On multivariate analysis, age >40 years, male gender, metabolic syndrome (MS), diabetes mellitus (DM), abdominal obesity, hypertension, dyslipidaemia and obesity were found as the risk factors for NAFLD. There were no differences in sociodemographic characteristics, DM, MS, abdominal obesity, hypertension and dyslipidaemia between non-obese and obese NAFLD (all p>0.05).
CONCLUSION: In this community study in Bangladesh, NAFLD was present in 18.5% participants, one-quarter of whom were non-obese. Apart from body mass index, the metabolic profile was comparable between obese and non-obese NAFLD. Public health measures are needed to control and prevent NAFLD and MS and their adverse health consequences. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  diabetes mellitus; fatty liver; liver; nonalcoholic steatohepatitis; obesity

Year:  2020        PMID: 33376110     DOI: 10.1136/bmjgast-2020-000535

Source DB:  PubMed          Journal:  BMJ Open Gastroenterol        ISSN: 2054-4774


  7 in total

1.  Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome.

Authors:  Punyisa Boonchai; Chayanis Kositamongkol; Suchanart Jitrukthai; Sukumal Phothirat; Euarat Mepramoon; Pongpol Nimitpunya; Weerachai Srivanichakorn; Thanet Chaisathaphol; Chaiwat Washirasaksiri; Chonticha Auesomwang; Tullaya Sitasuwan; Rungsima Tinmanee; Naruemit Sayabovorn; Phunchai Charatcharoenwitthaya; Pochamana Phisalprapa
Journal:  J Clin Med       Date:  2022-04-26       Impact factor: 4.964

Review 2.  Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease.

Authors:  Stanislav Kotlyarov; Aleksei Bulgakov
Journal:  Cells       Date:  2021-11-01       Impact factor: 6.600

Review 3.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10

4.  Impact of chronic hepatitis on cardiovascular events among type 2 diabetes patients in Taiwan pay-for-performance program.

Authors:  Chih-Cheng Hsu; Wen-Chen Tsai; Yi-Jing Sheen; Pei-Tseng Kung; Li-Ting Chiu
Journal:  Sci Rep       Date:  2022-07-09       Impact factor: 4.996

5.  Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome.

Authors:  Suchanart Jitrukthai; Chayanis Kositamongkol; Punyisa Boonchai; Euarat Mepramoon; Pinyapat Ariyakunaphan; Pongpol Nimitpunya; Weerachai Srivanichakorn; Thanet Chaisathaphol; Chaiwat Washirasaksiri; Chonticha Auesomwang; Tullaya Sitasuwan; Rungsima Tinmanee; Naruemit Sayabovorn; Phunchai Charatcharoenwitthaya; Pochamana Phisalprapa
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964

6.  Mid-upper arm circumference is associated with liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease: A population based observational study.

Authors:  Xiaoxiao Wang; Xiaohe Li; Rui Jin; Jia Yang; Rui Huang; Lai Wei; Feng Liu; Huiying Rao
Journal:  Hepatol Commun       Date:  2022-05-13

Review 7.  NAFLD in normal weight individuals.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Diabetol Metab Syndr       Date:  2022-03-24       Impact factor: 5.395

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.